I write about growth industries focusing on their best stock buys on Seeking AlphaConsultant, business management and development.
Former President of Sappanos Decorating Centers, Chicago, with more than 70 employees. Sold in 2010. Sold all our properties in excess of $10m.
Former Research and Teaching Fellow, Harvard and Assoc. Professor Tufts Medical School.
Currently teach business and politics at university in Tel Aviv, write a column for the Jerusalem Post in Business and Finance, and do business management and development consulting to start-ups and struggling companies.
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies. Licensed Investment Advisor.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
Dendrites are the thousands of branching extensions of neurons, each fine-tuned to detect important inputs. My collaborators and I have backgrounds in the physical and biological sciences, particularly neuroscience. We perform empirically based research to identify extraordinary opportunities.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution. My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector. I am a contributing writer at CNA Finance and cover emerging opportunities as well as breaking news events.
Equity Flux offers its clients financial consultancy services. We pride ourselves on our ability to provide you with the latest research, news, views and opinions. We aim to build long term relationships by helping our clients and partners create sustainable value for their own businesses.
Currently going for MBA in finance. Personally invest mainly in biotechs and all opinions are my own. Follow me @KeithStokes14 on twitter (I discuss trades and companies, mainly small-cap biotechs).
Christopher Grosvenor, CFA, CMT, a nine-year finance professional, provides clients with bottom up company and industry research. He believes that this is the best way to generate alpha for clients. Chris specializes in the enterprise application industry, and broadly the technology, media, and telecom sectors. He also manages a portfolio and was a financial advisor at Merrill Lynch.
Readers should judge the suitability of investments in light of their own unique circumstances.
Over 20 years investing in small/mid cap stocks. Founder of Spotlight Funds and predecessor Spotlight Capital. Former Co-PM of $1.5B CRM SmallCap Fund. Former analyst at Prudential Investments. Harvard MBA, Notre Dame BBA, CFA.
Reformed Wall Street analyst turned Investment Consultant. Hoping to share my ideas with individuals. Follow me on twitter for all free ideas across all platforms.
In the series "What's Working". I discuss the fundamentals behind technically strong stocks. The chart may look good but why does it look good. Is the fundamental reason for the move sustainable? Is it too expensive to chase? The goal is to offer you new ideas with a fundamental understanding of why the stock is working; not a complete thesis, a short article to jump start for your own process.
JD Bloomington is a registered investment advisor and special equities analyst. Mr. Bloomington was co-founder of the Bloomington long-short equity hedge fund founded in 1996. Mr. Bloomington is a sought out expert speaker at industry conferences, including the annual conferences of the of the HFA, HedgeCo, HFIA, and many more
Mr. Bloomington specializes in tax selling candidates and contrarian trades. Mr. Bloomington also founded Equity Think Tank which is a key component in identifying and researching many of his stock selections.
“one of the last great advocates of reason”
We manage a hedge fund that utilizes value investing principles and rigorous analysis.
Prospective investors, financial reporters, etc. can reach us using the Seeking Alpha messaging platform.
We are a research group that consults hedge fund and high-net worth clients. We specialized in identifying special opportunities from both the long and short side. The writer for 3D Analytics has professional traded for hedge funds for 10+ years and specializes in 1) finding hidden, unrecognized value, 2) shorting overvalued stocks, and 3) arbitrage situations. The articles are written solely by him, but has a group that assist him in finding opportunities, basic research, and editing.
OMF is a full service Foreign Exchange, Futures, Options and Equities brokerage firm. We focus on delivering comprehensive trading advice and service to our clients in an honest, disciplined and timely manner. We have a strong and established market reputation spanning over 25 years.
Mr. Novik founded PROLOR Biotech, Inc., a biopharmaceutical company developing long-acting therapeutic proteins, in 2005, and served as its President through its acquisition by OPKO Health (NYSE: OPK) in 2013, a $560 million transaction. Mr. Novik is a co-founder of GlassesOff, and previously served as Chief Operating Officer and Head of Strategic Planning of THCG, a technology and life sciences investment company. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. THCG's own portfolio included several life sciences and medical devices companies. Mr. Novik earned his M.B.A. degree, with Distinction, from Cornell University.
Maredin Capital Advisors (Maredin) is a boutique, independent, Registered Investment Advisor, based in Miami, Florida. It was founded in 2005 by Marcelo Zinn and is based on the Value Investing philosophy founded by Benjamin Graham and popularized by his most famous student Warren Buffett.
At Maredin we pride ourselves on delivering financial services/products which help people and firms attain their financial goals. This is done through consultation with our clients, independent research and analysis, and a clear focus on long-term results.
Maredin manages three funds and Separately Managed Accounts ("SMA"). Each fund is intended for a specific audience yet share the same manager and philosophy.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
BioGroup Team (BGT) is a self-organized panel of professionals with a shared interest in trading and investing in the healthcare and life sciences sectors. Our experts’ editorial team is comprised of individuals with extensive background in research, science, economics and trading in the biotechnology / health sectors.
Our main focus is identifying and analyzing cutting edge biotechnology companies that are under or over-valued. We obtain information from public sources that we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our aim is to deliver a succinct analysis which is clear and detailed enough to provide the reader with a better understanding of our findings and conclusions.
Harlan currently works as a Research Associate specializing in Investment Communications.
Prior to his current role, Harlan spent seven years in investment management. The first two years were spent creating portfolios for retail investors, followed by five years in Market Risk for a major global bank
Harlan earned his Bachelor's degree in Economics followed by a Master's degree in Urban and Regional Economics
Gemstone Equity Research provides in-depth and research driven trading insight to individuals and institutional investors. Our team constantly looks for companies to cover in technology and services sector, which enables us to provide timely and actionable investment ideas to our clients.
We achieve our goals through intense focus and discipline. We hope to share our knowledge through this platform.
Steve Andrew is an analyst for an east coast based money manager (2007-present). He focuses primarily on small cap growth companies. He is a graduate of Virginia Tech's Pamplin School of Business with a degree in finance.
Dallas currently owns and operates as CEO an Austin-based enterprise consulting firm that specializes in private company lifecycle management, up to and including taking companies public, and in helping consult publicly traded companies ranging in market cap from $100 million to $500 million. He has a specialization in deal flow management and is often the referring and closing source of Joint Ventures and broader M&A. Dallas often works directly with management teams and Boards of microcap and stressed equity companies in which he or members of his professional network are heavily invested. This includes helping with overall strategy, helping with capital structure management, helping facilitate liquidity, helping facilitate Joint Ventures and broader M&A, and helping restructure the business segments if necessary. Recently Dallas has been interviewed by The Pittsburgh Business Times, The Banker, Columbus Business First, Houston Business Journal, The Deal, Energy Intelligence, and his tweets have been used by CNBC to highlight hot button issues regarding Carl Icahn, Bill Ackman, Nelson Peltz’s takeover attempts at DuPont, etc. Dallas has also been quoted and sourced to by StreetSweeper.org, Marcellus.com, MarcellusDrilling.com, Bakken.com, OilOnline.com, and other physical and online publications. "One place of great inefficiency is in the stressed equity markets – or the markets in which a company appears as bankruptcy or a breakup is inevitable. As equities become stressed they often sell down to absurd levels of value that present, should there be value to be unlocked, opportunities for “venture level” returns. These often range in the 3X-10X range. With my unique ability to actually improve business outcomes by working directly with a company and management/Board I’m in a position, should I view the underlying business as salvageable, to directly improve the long-term viability of the company. I am NOT simply an investor in these names but an acting consultant. This allows me to “overlay my network” and to move the company away from a stressed or defaulting outcome and into an outcome probability that allows the equity price to move substantially higher. Identifying these opportunities has generated shareholders and investors thousands of percentage points in aggregate and is something I’m often recognized by paying subscribers for."
Disclaimer and disclosure: It is probable that the author and his associates have a position in the subject securities consistent with the opinion expressed in this article and they reserve the right to buy and/or sell the securities mentioned in this article, at any time without further notice.
Zorro Trades attempts to utilize fundamental analysis to identify securities and then gain an idea of when to enter said security via technical analysis.
Have been investing in stocks for over 25 years. Worked on Wall Street on the equity side of the business. Now invest in both public and private equity. Try to identify Overlooked and Underfollowed names set up for outsized returns.
Over 20 years experience in investing, modeling, forecasting, and analytics. I concentrate my investment research on small to mid-cap medical device and biotech companies. My trading style is mostly catalyst-based (catalyst with likely success), generally holding stocks from days to weeks, relying on the catalyst as a potential backstop; a smaller allocation of funds goes to longer-term picks.
In previous years, I published a small-cap medical stock newsletter, which featured the the opinions of medical practitioners.
Mitchell is the founder of Options Risk Management and an independent agent at Hummel Insurance (representing companies such as Progressive, Auto-Owners, Safeco, Western Reserve, and many others). Born in Cincinnati, OH, he has lived in southeast Indiana his entire life (near Rising Sun). His 8 year trading experience includes equities, ETFs, options, futures, forex, and even bitcoins. He started by learning technical and fundamental analysis and in recent years has studied the importance of watching unusual options activity to see where the big money is positioning. Mitchell ran a premium trading subscription service from the start of 2013 through August 2015 where he provided market insight to 100+ members. Early in 2014, he started teaching on an individual basis via 1 on 1 equity/options mentoring. These customized courses help investors and traders learn technical/fundamental analysis, trading on unusual options activity, options basics to advanced strategies, options greeks, volatility, and positioning for earnings and other catalysts. Mitchell is also a contributor to TraderPlanet and See It Market (previously at Seeking Alpha and TheStreet.com). You can follow him on Twitter and StockTwits for daily market commentary as well.
You can reach him at Mitchell@OptionsRiskManagement.com for details on 1 on 1 mentoring.
You can reach him at firstname.lastname@example.org for your insurance/financial services needs.
Connect with Mitchell on social media: Twitter StockTwits Facebook LinkedIn Google+
Matt Stewart is a private investor, former vice president & director of RBC Dominion Securities Inc. in Toronto and holds an Honors BA from the University of Western Ontario and an MBA from the F.W. Olin School of Business at Babson College. Matt also represented all BCE common shareholders as the 'intervenor' in the BCE v. Bondholder's case argued before the Supreme Court of Canada in July, 2008.